RxDoctor Payments Data

Kinan Rahal, MD

Gastroenterology · Sarasota, FLNPI 1639278708

Payments from drug & device makers

$456in general payments, 2019–2025

Across 13 payments — averaging $35.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Madrigal Pharmaceuticals$147
  • Aimmune Therapeutics, Inc.$125
  • Boston Scientific$60
  • AbbVie$48
  • Mauna Kea Technologies, Inc.$28
  • Johnson & Johnson$18
  • plus $31 from 2 others

What the payments were for

  • Food & beverage$42593%
  • Education$164%
  • Gifts$143%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$456 in reported general payments places this provider in the 15th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$490,644
Medicare patients
1,717
Services billed
6,152

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab11$334,445
CreonLipase/Protease/Amylase33$123,796
ZenpepLipase/Protease/Amylase14$40,628
LinzessLinaclotide47$32,943
Mesalamine29$32,089
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates250$16,160
MotegrityPrucalopride Succinate14$9,530
Pantoprazole Sodium660$6,510
Esomeprazole Magnesium65$5,727
ClenpiqSod Picosulf/Mag Ox/Citric Ac30$5,182
Colestipol Hcl51$4,095
Omeprazole281$3,932
Mesalamine ErMesalamine11$3,249
Ursodiol11$2,321
Famotidine205$2,123

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$18$334,44511 claims
AbbVieCreon, Linzess$48$156,73980 claims
Aimmune Therapeutics, Inc.Zenpep$125$40,62814 claims
Braintree Laboratories, Inc.Sutab$14$1,96712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →